IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study

Journal article

Peer reviewed

Abdo A. Elfiky and Wael M. Elshemey

Medicinal chemistry research, Vol.25(5), pp.1005-1008

01/05/2016

PMCID: PMC7080126

PMID: 32214769

Abstract

IDX-184

NS5B

Nucleotide inhibitors

Original Research

QSAR

Sofosbuvir

1 Record Views

Title: IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study
Creators - without role: Abdo A. Elfiky - Cairo University
Wael M. Elshemey - Cairo University
Publication Details: Medicinal chemistry research, Vol.25(5), pp.1005-1008
Publisher: Springer US
Identifiers: 9916837008331
Academic Unit: Islamic University of Al Madinah
Language: English
Resource Type: Journal article